Survodutide
Survodutide is an experimental single-molecule dual agonist of the GLP-1 and glucagon receptors studied for chronic weight management and for MASH (formerly NASH). A published Phase 2 trial in MASH reported improvements in liver histology, and Phase 2 obesity data showed substantial weight reductions; a Phase 3 program (SYNCHRONIZE) is ongoing. It remains investigational and is not authorized for clinical use.
Mechanism
In plain terms, survodutide mimics two hormones at once to reduce appetite and influence how the liver and body handle fat and sugar. Technically, it is a synthetic peptide that simultaneously agonizes the glucagon-like peptide-1 (GLP-1) receptor and the glucagon receptor. GLP-1 activity promotes satiety and glucose-dependent insulin secretion, while glucagon-receptor agonism is thought to increase energy expenditure and hepatic lipid metabolism, a combination proposed to drive weight loss and reduce liver fat.
Regulatory Status by Region
- United States (FDA)Investigational; not approved. Being evaluated in a Phase 3 program (SYNCHRONIZE) for obesity, with additional trials in MASH.
- Australia (TGA)Not entered on the Australian Register of Therapeutic Goods (ARTG); investigational only and not approved for supply.
- European Union (EMA)Not authorized; investigational, no marketing authorization.
- WADANot listed on the WADA Prohibited List. As an investigational incretin-class agent (a GLP-1/glucagon dual agonist) it is not a banned substance.
Key Studies
- A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis (Sanyal et al.) (N Engl J Med 2024)